Authors:
Address: The First Department of Cardiovascular Internal Medicine, Chinese PLA General Hospital, China.
Journal:

Publication:

abstract

OBJECTIVE:

To investigate the inhibitor of matrix metalloproteinase-2 (MMP-2) (2R)-2-[5-[4-[ ethyl-methylamino] phenyl [thiophene-2-sulfonylamino]-3-methylbutyric acid (TISAM) therapeutic effect on experimental autoimmune myocarditis (EAM) in Lewis rats.

METHODS:

treatment protocol of oral administration of 5 mg/kg TISAM once a day for 14 days was performed on EAM Lewis rats. EAM Lewis rats were divided into 3 groups: treatment in early, middle and later stage respectively (n = 20). After experiment at the designate time point, the rats were euthanatized and hearts were harvested. Cardiac inflammatory score, fibrosis score and content, and infiltration of macrophages and T lyminflammatory score, fibrosis score and content, and infiltration of macrophages and T lymphocytes, message RNA (mRNA) expression of matrix metalloproteinase (MMP)-2 and MMP-9 and protein activity of gelatinase were determined.

RESULTS:

TISAM treatment in early phase was invalid (treatment started from the creation of the model), treatment in middle and later phase was effective (treatment started from 7 and 14 day after the creation of the model).

CONCLUSION:

Inhibitor of MMP-2 can block ventricular remodeling in middle stage in EAM Lewis rats. The mechanism maybe alleviate the inflammatory cell cardiac infiltration, decrease the mRNA expression of MMP-2 at transcript level and downregulate gelatinase activity at protein level.

Related Articles
[Effects of matrix metalloproteinase-9 inhibitor in Lewis rats with experimental autoimmune myocarditis].
Zhonghua Xin Xue Guan Bing Za ...
[Effects of matrix metalloproteinase-9 inhibitor in Lewis rats with experimental autoimmune myocarditis].
Han LN, Li TL, Zhang YJ, Yang TS, Ding Y, Zhao XN, Guo SL. Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Feb; 39(2):118-23.
Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease.
Exp Mol Pathol. 2008
Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease.
Liu W, Feng W, Wang F, Li W, Gao C, Zhou B, Ma M. Exp Mol Pathol. 2008 Jun; 84(3):213-7. Epub 2008 Mar 7.
Adenovirus-mediated ICOSIg gene transfer alleviates cardiac remodeling in experimental autoimmune myocarditis.
Immunol Cell Biol. 2008
Adenovirus-mediated ICOSIg gene transfer alleviates cardiac remodeling in experimental autoimmune myocarditis.
Liu W, Feng W, Wang F, Li W, Zhou B, Gao C, Li Y, Kong Y, Ma M, Fu S. Immunol Cell Biol. 2008 Nov-Dec; 86(8):659-65. Epub 2008 Jul 1.
Matrix metalloproteinase (MMP)-9, but not MMP-2, is involved in the development and progression of C protein-induced myocarditis and subsequent dilated cardiomyopathy.
J Immunol. 2009
Matrix metalloproteinase (MMP)-9, but not MMP-2, is involved in the development and progression of C protein-induced myocarditis and subsequent dilated cardiomyopathy.
Matsumoto Y, Park IK, Kohyama K. J Immunol. 2009 Oct 1; 183(7):4773-81. Epub 2009 Sep 4.
Review Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis.
Inflamm Allergy Drug Targets. ...
Review Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis.
Watanabe K, Sukumaran V, Veeraveedu PT, Thandavarayan RA, Gurusamy N, Ma M, Arozal W, Sari FR, Lakshmanan AP, Arumugam S, et al. Inflamm Allergy Drug Targets. 2011 Jun; 10(3):218-25.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster